indicates that the transmembrane region plays a pivotal role in the agonist-independent activity of this receptor. BAY36-7620 will be useful to further delineate the functional importance of the mGlu1 receptor, including its putative agonist-independent activity.
The existence of numerous mGlu receptor subtypes and splice variants makes the need for highly selective and potent agonists and antagonists crucial for physiological and therapeutical studies of mGlu receptors. Indeed, within recent years, a number of ligands selective for the individual groups of mGlu receptors have been developed ( ; ). However, the high degree of conservation Pin et al., 1999 Schoepp et al., 1999 of the agonist binding pocket between mGlu receptors from the same group ( ) is such that only very few subtype Parmentier et al., 2000 selective compounds acting on this site have been identified ( ; ) . Moreover, these compounds display a very Pin et al., 1999 Schoepp et al., 1999 low affinity that precludes their usefulness in identifying the physiological roles of these receptors. Recently, selective non-competitive antagonists have been identified for mGlu1 (CPCCOEt) and mGlu5 (MPEP) ( ; ; ). Hermans et al., 1998 Litschig et al., 1999 Pagano et al., 2000 Notably, the structures of both compounds are unrelated to that of Glu ( ), and both were found to interact directly within the Fig. 1 transmembrane (TM) region of the receptors ( ; ). Thus, mGlu receptors can be specifically regulated by Litschig et al., 1999 Pagano et al., 2000 compounds, with diverse structures, acting on sites other than the Glu binding site.
An increasing number of constitutively active receptors i.e. active in the absence of an agonist -have been described, especially among -the rhodopsin-like receptors. Thus, it has been proposed that GPCRs naturally oscillate between active and inactive states in the absence of agonist binding (  ;  ;  ; ). As such, agonists stabilize the active state, Cotecchia et al., 1990 Kjelsberg et al., 1992 Leff, 1995 Samama et al., 1993 whereas antagonists do not. Among the antagonists, those that stabilize an inactive state can inhibit not only the agonist-induced activation of the receptor, but also its constitutive activity. Such antagonists are called inverse agonists. For most constitutively active GPCRs characterized to date, numerous competitive antagonists display inverse agonist activity. Such compounds are very useful for the understanding of the possible physiological relevance of GPCR constitutive activity ( ; ; ; Arvanitakis et al., 1998 Barker et al., 1994 Bond et al., 1995 . 1999
We have previously shown that mGlu5 as well as mGlu1a receptors display agonist-independent activity ( ; Joly et al., 1995 Prezeau et al., ) . However, none of the described competitive antagonists for mGlu1 or mGlu5 receptors, which act in the ECD, have inverse agonist 1996 properties ( ). The first mGlu receptor inverse agonist described was MPEP, a non-competitive mGlu5 receptor antagonist Prezeau et al., 1996 acting in the TM region rather than in the ECD ( ). However, CPCCOEt, a selective mGlu1 non-competitive antagonist also Pagano et al., 2000 interacting within the TM region, did not show any significant inverse agonist activity ( ). Litschig et al., 1999 A new compound, BAY36-7620 ( (3aS,6aS)-6a-Naphtalen-2-ylmethyl-5-methyliden-hexahydro-cyclopental c furan-1-on ; ), has
Fig. 1 recently been found to inhibit the Glu-induced activation of PLC-coupled mGlu receptors in cultured neurons (described in abstract form; Mü corresponding with an identical sequence in mGlu1 (Lys692-Ile693-Cys694). These new restriction sites were then used to generate the constructs given in as follows: the EcoRV site was used to exchange the first half of the extracellular domain (chimeras A & B), the Fig. 7A NheI site was used to exchange the extracellular domain (chimeras C& D) , and exchange of the extracellular domain plus the first three TMs (chimera E) was performed using the Bgl II site located in the sequence coding for the i2 loop. For chimera F, we subcloned the fragment Nhe I Bgl II of mGlu5 into mGlu1.
-

Culture and transfection of HEK 293 cells
HEK 293 cells were cultured in Dulbecco s modified Eagle s medium (DMEM) supplemented with 10 fetal calf serum and transfected by ' ' % electroporation as previously described ( ). Briefly, electroporation was carried out in a total volume of 300 l with 10 g Gomeza et al., 1996 μ μ carrier DNA, plasmid DNA containing mGlu1a (0.3 g), mGlu5a (0.3 g), mGlu2 (2 g), mGlu3 (2 g), mGlu4a (5 g), mGlu6 (5 g), mGlu7a
μ μ μ μ μ μ (5 g) or mGlu8a (5 g) and 10 million cells ( ). Group-I mGlu receptors naturally couple to phospholipase C (PLC), but the μ μ Brabet et al., 1998 group-II and -III subtypes do not. Thus, to enable coupling of the group II and III mGlu receptors to PLC, the receptors were coexpressed with the chimeric G-protein subunit Gqi9 in which the carboxyl terminal 9 residues of Gq are replaced by those of Gi2 ( ; et al., 1993 ; ) . mGlu6 was however co-expressed with the non-selective PLC-activating G15 subunit ( Gomeza et al., 1996 Parmentier et al., 1998 ). The pharmacological profiles of mGlu2 and mGlu4 determined using this method of coupling to PLC have been Offermanns and Simon, 1995 shown to be identical to those determined by measuring the inhibition of cAMP formation ( ). As Glu concentration in the Gomeza et al., 1996 culture medium profoundly affects the functioning of mGlu5a and mGlu3 receptors, these receptors were co-expressed with the high affinity
Glu transporter EAAC1 (
). Kanai and Hediger, 1992 
Determination of accumulation of inositol phosphates (IP)
Determination of IP accumulation in transfected cells was performed ( ) after labeling the cells overnight with H Brabet et al., 1998
-myo-inositol (23.4 Ci/mol). The cells were pre-incubated for 1 hour with the Glu degrading enzyme glutamate pyruvate transaminase (1U/ml) and 2 mM pyruvate to avoid the possible action of Glu released from the cells. The stimulation was then conducted for 30 min in a medium containing 10 mM LiCl, glutamate pyruvate transaminase, pyruvate and the indicated concentration of agonist. Results are expressed as the ratio between the radioactivity of collected in the IPs fraction over the radioactivity recovered from the solubilized cellular membranes. The use of this ratio over IP formation alone, allows for greater homogeneity in the data, as this reduces any variation in the raw data attributable to differences in cell number in individual wells. The normalized IP formation were determined as a percentage of IP formation ratio compared to that obtained with the submaximal Glu concentration used in the described experiments and referred as 100 .
%
Membrane preparation and H -Quisqualate Binding Assay
[ 3 H QA binding was performed in HEK293 cells cultured and transiently transfected with mGlu1as receptor as described above. KCl 4.7mM, CaCl 1.8mM, glucose 5.6mM, pH 7.4), homogenized, pooled and centrifuged at 40,000g for 20 min. The resulting pellet was 2 resuspended in the same buffer, homogenized and stored as pellets at 20 C until use (< 1 month). Protein levels were determined using a −°b icinchoninic acid assay ( ) with bovine serum albumin as a standard. Smith et al., 1985 Binding conditions used were communicated by Dr. C. Romano (personal communication) and performed and modified as follows.
Binding experiments were carried out in a buffer containing HEPES 40mM and CaCl 2.5mM, adjusted to pH 7.4 with NaOH. Membrane 2 pellets were resuspended in the above buffer plus protease inhibitor cocktail and aliquots of 50 g protein were incubated in the presence of H
QA (specific activity 25Ci/mmol), in a final volume of 100 l at room temperature, for one hour. Competition experiments were performed with μ 600nM H QA and varying concentrations of cold QA and BAY36-7620. Incubation was terminated by rapid filtration through Whatmann
QF/C filters, (pre-soaked for 45 min in 3 powdered milk), using a Brandel Harvester. Filters were rinsed in HEPES/CaCl buffer and counted % 2 in 3ml PCS scintillant. Non-specific binding was determined in the presence of 1mM Glu.
Data presentation and Statistics
C u r v e s w e r e f i t t e d w i t h K a l e i d a g r a p h s o f t w a r e u s i n g t h e e q u a t i o n
where the EC is the concentration of the compound necessary to 50 obtain 50 of the maximal effect and nH is the Hill coefficient. Statistical analysis was performed using Microsoft Excel software. Where
appropriate one way analysis of variance were performed followed by post-hoc Students T-Test with 0.05. All t-tests used 2-way critical
values, and only the pertinent values are given.
Results
BAY36-7620 is a specific mGlu1 receptor antagonist
BAY36-7620 ( ), has been found to antagonize the action of group-I mGlu receptor agonists on cerebellar granule neurons maintained Fig. 1 in culture ( ), suggesting that this new compound is an mGlu1 receptor antagonist as this receptor is the predominant group-I M ller et al., 2000 ü mGlu receptor present in these cells ( ). Prezeau et al., 1994 The effect of BAY36-7620 on the production of inositol phosphates (IP) following receptor stimulation of phospholipase C, was first examined in cells transiently expressing one of the group-I mGlu receptors, mGlu1a or mGlu5a. BAY36-7620 did not activate these receptors at concentrations up to 10 M ( ). To test for an antagonistic effect of BAY36-7620 on mGlu1 or mGlu5 receptors, cells were stimulated μ Fig ± % μ BAY36-7620 and a total inhibition was observed with 10 M BAY36-7620 on mGlu1 receptors whereas no effect was seen on mGlu5 Table 1 To further characterize the selectivity of action of BAY36-7620, its effect on all other mGlu receptor subtypes was examined. The same index of receptor activation as for group-I mGluRs i.e. IP formation -was used. To that aim, the Gi/o-coupled group-II and III mGluRs were --co-expressed with either a chimeric G qi protein, or the ubiquitous G 15 protein, as previously described (see the Material and Methods ). A small response was detected in cells expressing mGlu8 receptor, equal to 36.9 13.3 of the effect obtained with 1 mM Glu on mGlu1
receptor. This effect was concentration-dependent with an EC of 15.8 2.6 M, 100 fold higher than the IC determined on mGlu1 receptor 50 ± μ
50
(data not shown). However, we noted that the slope of the curve was very steep, the Hill coefficient being 5.32 0.59, suggesting a complex ± effect of BAY36-7620 on this receptor subtype. BAY36-7620 may be an allosteric activator, which facilitates the action of low residual Glu in the medium. When tested as an antagonist, BAY36-7620 was found not to inhibit the Glu-induced activation of mGlu2, 3, 4, 6, 7, or 8 receptors ( ). Together, these results indicate that BAY36-7620 is a potent and specific mGlu1 receptor antagonist. Fig. 3 
BAY36-7620 is an inverse agonist of mGlu1a receptors
Numerous antagonists at family 1 GPCRs inhibit constitutive activity of either wild-type or mutated receptors, and are thus referred to as inverse agonists ( ). However, no known competitive group-I mGlu receptor antagonists nor the non-competitive Arvanitakis et al., 1998 antagonist CPCCOEt have been found to inhibit the constitutive activity of these receptors ( ; ). Litschig et al., 1999 Prezeau et al., 1996 However, we decided to ascertain whether this novel antagonist had observable inverse agonist activity.
Indeed, BAY36-7620 significantly inhibited the basal production of IP by approximately 36 at 10 M ( ; t 2.9, p<0.05). Table 1 conditions, when incubated in the presence of Glu, BAY36-7620 decreased the IP production to a level significantly lower than the basal level (t 2.3, p<0.05 and t 3.9, p<0.05 in the presence of G q), indicating that BAY36-7620 inhibited not only the activation of the
receptor by Glu, but also its basal activity. As a control, MCPG (3mM), a non-specific competitive mGlu1 receptor antagonist whilst significantly inhibiting the Glu-induced stimulation of IP (t 2.4, p<0.05), did not inhibit the constitutive activity of mGlu1a receptors (
). These data demonstrate that BAY36-7620 is a potent inverse agonist at mGlu1a receptor. Fig. 4B 
BAY36-7620 is a non-competitive mGlu1 receptor antagonist
To ascertain the mechanism of antagonism by BAY36-7620, concentration-response curves for Glu were generated in the presence of 0, 
respectively, indicating that BAY36-7620 did not inhibit the receptor in a competitive manner. We observed that the EC of Glu also increased 50 as the concentration of BAY36-7620 increased, whereas the Hill coefficient of the Glu concentration-response curves was not affected by increasing the concentration of BAY36-7620.
Further confirmation of the non-competitive nature of BAY36-7620 was sought through analysis of binding of H QA, a potent group-I
mGlu receptor agonist known to bind at the Glu binding site ( ), to HEK293 cell membranes expressing mGlu1a. As shown Schoepp et al., 1999 in , BAY36-7620 was not effective in displacing the binding of 600nM H QA on mGlu1, up to 100 M (F 0.37, p>0.05), whereas Fig. 6 [ 3 ] μ (2,26) = cold QA did so (the specific binding was 45 6 of the total binding of H QA). Moreover, the capability of cold QA to displace H QA was
not modified by the presence of 10 M of BAY36-7620, since its Ki values were 109 nM and 85 nM, in the absence and in the presence of μ BAY36-7620 respectively (F 7.4, p<0.05; ) . These data are consistent with BAY36-7620 acting at a site different from the Glu (2,11) = Fig. 6 binding site.
BAY36-7620 is likely to interact within the transmembrane region of mGlu1 receptor
The previously described non-competitive group-I mGlu receptor antagonists, CPCCOEt and MPEP, have been reported to bind within the TM region of mGlu1 and mGlu5 receptors respectively ( ; ). We therefore examined the effect of Litschig et al., 1999 Pagano et al., 2000 BAY36-7620 on various chimeric receptors in which the ECD had been swapped between mGlu1 and the drosophila receptor DmGluA, or between mGlu1 and mGlu2. As shown in , BAY36-7620 did not inhibit the action of Glu on receptors possessing the ECD of mGlu1 Fig. 7 receptor and the TM region of either DmGluA or mGlu2 receptors. However, BAY36-7620 fully antagonized the action of Glu on the chimeric mGlu2/1 receptor containing the TM region of mGlu1 receptor and ECD of mGlu2 receptor. On this chimeric receptor, the inhibitory effect of BAY36-7620 was also concentration-dependent with an IC value of 0.14 0.05 M, not notably different from that measured on the 50 ± μ wild-type mGlu1 receptor ( ). Taken together, these data revealed a crucial role played by the TM region of the mGlu1 receptor for the Table 1 action of BAY36-7620 on this receptor subtype.
To further identify the molecular determinants controlling the specificity of BAY36-7620, a series of chimeric receptors possessing various parts of the ECD and TM regions of the mGlu1 and mGlu5 receptor subtypes were constructed. A schematic representation of these chimeric receptors is shown in . Analysis of the action of BAY36-7620 on these chimeric receptors confirmed that the antagonist action of this still responsive to BAY36-7620 ( , chimera F; t 7.98, p<0.05), with a potency only three times lower than that measured on the Fig. 8B (df 7) = = wild-type mGlu1 receptor ( ). Indeed, the potency of BAY36-7620 on chimeras C and F is close to the potency on mGlu1 receptor (  Table 1 Fig .   , ). In contrast, the chimera E containing the first three TMs of mGlu1 receptor and the last four of mGlu5 receptor ( , chimera 8C Table 1 Fig . 8B E; t 3.23, p>0.05) is not sensitive to antagonism by BAY36-7620. These data indicate that residues crucial for the specific action of (df 2) Most of the family 3 receptors are constituted of two large domains, the ECD and the heptahelical TM region which is responsible for the coupling to the G-protein ( ). The ECD, that contains the ligand binding site, can exist as at least two different forms, an Bockaert and inactive open one, and an active closed one, as suggested by several mutagenesis and modeling studies (see for example ; Bessis et al., 2000 ) and recently demonstrated by the determination of the crystal structure of the ECD of mGlu1 receptor ( Galvez et al, 2000 Kunishima et al.,
). Then, it was thougth that the constitutive activity of the family 3 receptor could be due to the spontaneous closure of the ECD. Indeed, 2000 some studies showed that mutations in the ECD of the CaSR resulted in constitutively active receptor ( ). But the natural Jensen et al. 2000 constitutive activity of mGlu1 and mGlu5 receptors does not result from the equilibrium of the ECD between an active and an inactive state.
First, the six known competitive antagonists (ABHD-I, bromo-homo-ibotenate, MCPG, 4CPG, 4C3HPG and ACPT-III, (see ; Joly et al., 1995 ) and Parmentier and Pin, unpublished data) that bind to the ECD of mGlu1 and mGlu5 receptors, do not block their natural Prezeau et al., 1996 constitutive activity. Indeed, all these competitive antagonists behave as neutral antagonists. Second, only non-competitive antagonists (such as MPEP and BAY36-7620), acting directly in the TM region, are able to block the constitutive activity. This suggests that the agonist-independent activity of mGlu1 receptors can not be blocked by acting directly in the agonist binding pocket. This is in contrast to what has been demonstrated for many Rhodopsin-like receptors, for which competitive antagonists behave as inverse agonists. Our finding that BAY36-7620 has inverse agonist property on mGlu1a receptor is therefore of interest to increase understanding of the specific molecular mechanisms responsible for the agonist-independent activity of the family 3 receptors.
In contrast to all competitive Glu-like antagonists, we found that BAY36-7620 interacts in a specific site distinct from that of Glu. Indeed, BAY36-7620 did not displace H QA from its binding site, nor did it affect the affinity of cold QA. Moreover, the antagonist action of
BAY36-7620 was found not to be competitive, since the maximal Glu-induced activation of mGlu1 receptor was decreased in the presence of high concentration of BAY36-7620. At low concentrations, BAY36-7620 did not decrease the maximal effect of Glu and did decrease significantly the EC value of Glu. Such an effect can easily be explained by the presence of spare receptors, as expected using transient 50 expression in HEK 293 cells. Indeed, a similar decrease in the glutamate EC value using a low concentration of a non-competitive antagonist 50 has also been reported with CPCCOEt ( ). Hermans et al., 1998 Our data using chimeric mGlu receptors revealed that the TM region of mGlu1 was necessary for the inhibitory action of BAY36-7620.
Moreover, its apparent affinity was the same whether the ECD was that of either mGlu5, mGlu2 or DmGluA receptors even though these later two ECDs share only 41 sequence identity with that of mGlu1 receptor. Within the TM regions, we found that TM4 to TM7 of mGlu1 % receptor were sufficient to create a BAY36-7620 site in mGlu5 receptor. This shows that in contrast to what has been observed for the selectivity of action of MPEP ( ), TM3 does not play a role in the selective recognition of BAY36-7620 in the mGlu1 Pagano et al., 2000 receptor. Amongst the TM4 to 7, TM6 is identical in all mGlu receptors, and as such cannot play a role in the specific recognition of BAY36-7620, but a few residues are different between mGlu1 and mGlu5 receptor in TM4, TM5 and TM7. Preliminary experiments have revealed that indeed, as observed with the other mGlu1 selective non-competitive antagonist, CPCCOEt ( ), TM7 of mGlu1 Litschig et al., 1999 appears critical for the action of BAY36-7620 (Carroll, Kuhn, Pin and Pr zeau, unpublished data). It has recently been proposed that CPCCOEt é and the mGlu5 selective non-competitive antagonist MPEP interact within a similar cavity found in both mGlu1 and mGlu5 receptors (Litschig Taken together, our study identified a new highly selective mGlu1 receptor antagonist that will be useful to further elucidate the action of this receptor subtype in the brain. Moreover, our data showed that BAY 36-7620 is an inverse agonist on mGlu1. As the constitutive activity of mGlu1 is under the control of alternative splicing ( ), this compound will be useful to help discriminate between some of the Prezeau et al., 1996 actions of mGlu1 variants. Our study further documents the observation that antagonists acting within the TM region of mGlu1 and mGlu5 receptors can inhibit their agonist-independent activity. Such an activity of these compounds shed some light on the specific role of the TM region of these receptors in their natural constitutive activity. Moreover, such an activity of BAY36-7620 and MPEP will be useful to elucidate pyridine), CPCCOEt (7-Hydroxyiminocyclopropan b chromen-1a-carboxylic acid ethyl ester) and L-glutamate.
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Fig. 2 BAY36-7620 alone has no effect on mGlu1 or mGlu5 receptors, however inhibits Glu-induced activation of mGlu1 but not mGlu5. A:
BAY36-7620 is selective for mGlu1a over mGlu5a. IP accumulation was measured in HEK 293 cells transiently expressing mGlu1a, or 5a which were incubated with BAY36-7620 ( representative of an experiment performed three times in triplicate is shown.
Fig. 6
BAY36-7620 does not affect H QA binding. Binding of 600nM H QA in HEK293 cells transiently transfected with mGlu1a was displaced by
cold QA, but not by BAY36-7620. The presence of BAY36-7620 does affect the displacement of H QA by cold QA. The presented data are from but has no effect on the 1/2 mGlu chimera. Data are expressed as the ratio of IP formation over the radioactivity present in the solubilized fraction of the membranes and a representative of an experiment performed three times in triplicate is shown. Fig. 8 
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The last four TM of mGlu1a are essential for the specificity of BAY36-7620. 
